TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intervention acceptability for coaches
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Craving of Cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-operative anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects Achieving ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall response rate measured by PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MATRICS battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Complications at 2 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Complications at 6 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Complications at 3 months
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Complications at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in olfaction perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Stereopsis at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Fusion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Simultaneous Perception at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from atrial fibrillation or other atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for radiological spread of the injectate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation associated lens opacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Growth differentiation factor-15 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS (pain score 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction (Verbal ranking scale 1-4)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confirmed response (CR, nPR, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mixed Meal Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning AM Serum Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline in SLP Parameters after Bronchodilator Reversibility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in SLP Parameters between Asthma Patients and Healthy Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgical safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Seroconverted Subjects Against HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analogue Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: International Knee Documentation Committee (IKDC) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative infectious morbidities
Endpoint domain: Adverse events/effects
Primary endpoint: changes in body weight - BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional connectivity of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MDS-UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum aggregation intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Successfully Treated Mild/Moderate Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Successfully Treated Bleeding Episodes (Mild/Moderate/Severe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hematological complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: organ response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak TD1414 Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Peak Serum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of LBR-responsive genes in oral cavity tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportional change in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Rearfoot Eversion Motion During Stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Relapsing by Week 16
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness at Stopping Distal Pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing Time for Donor Site Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression analysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biopsy results for DNA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative gastric residual volume of gastric fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Laryngoscopic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞,norm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,norm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous oxygen saturation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) Per RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Who Developed Hand-foot Syndrome (HFS)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Use of Supplemental Pain Medication Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptomatic Hemorrhagic Transformation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Extent of myocardial oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time course of myocardial oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin fibroblast radiosensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Continuous blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-invasive surface electromyography during MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak oxygen uptake assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of maximum VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of neural dynamics technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring glaucoma filtering surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Endpoint in Digital Symbol Substitution Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression-Free Survival (PFS) in the Overall Population
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival (PFS) in the Female Population
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With at Least 1 Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum of Ventricular Conduction Stability (V-CoS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amplitude and phase of circadian rhythm of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FOBT completion and return
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and frequency of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: changes in dental brushing behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of time within predefined glucose target range 80-150 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of GSI-136
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep quality during postoperative period
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage change in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Bone mass/bone density measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sample (Vit. D/Calcium)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Magnetic mismatch negativity brain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Seropositive for Anti-HAV Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in suicidal ideation severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal variation of NTBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VA-ECMO weaning failure defined as death
Endpoint domain: Mortality/survival
Primary endpoint: Diet induce thermogenesis (DIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical activity energy expenditure (PAEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy and macro-nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in nerve conduction studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Assessment in Dry Eye (SANDE) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Schirmers test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine and/or chemotherapy resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to decompensated heart failure requiring in-patient admission or ER visit or IV diuretic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: osteoporosis treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (KM-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phospho-S6 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dopamine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ABSSSI Lesion Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Aortic root dimension change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Dysfunctional Attitudes Scale Short Form (DAS-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Beliefs Scale (BS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Automatic Thoughts Questionnaire (ATQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Experienced Dose Limited Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: 4-Month Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Implant survival rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Symptom Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time 0 To Time Of the Last Quantifiable Concentrations [AUC(0-last)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to Infinite Time [AUC(0-infinity)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose measured by incidence of dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Benefit Rate (CR, PR, SD lasting at least 24 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Probability of Tolerability Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in alcohol withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 6-month persistent infection of HPV 16 or HPV 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional Shoulder Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Hemoglobin Levels Within the Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in MDS-UPDRS part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Biological marker of Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Apparent diffusion coefficient (ADC) of the kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in quantitative insulin sensitivity check index (QUICKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Raynaud's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Change in McAuley Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Health Status Based on Frailty Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions-Bipolar Mania Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in post-cesarean pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DaTscan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in steady-state plasma pharmacokinetics of TMC435
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Past three month physical IPV perpetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past three month sexual IPV perpetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Earnings in past month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gastrointestinal health score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: beginning peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: beginning bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immune response to DAPTACEL vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of INOpulse device malfunction and/or device failure leading to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of stenosis diagnosed by CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedure Success at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of response during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in T-regulatory Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of study-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with study-related unanticipated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with technically successful procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma concentrations of E2006
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of good medium-term responders
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Beck Depression Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain relief on Day 2 of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semiquantitative assessment of protein levels associated with myocardial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Imaging parameters associated with clinical outcome after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Willing to Assess Their Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oxygen and ventilator requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spiritual well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trunk-to-limb Fat Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PI3K-y changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes